BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Genetic Technologies: ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies Limited (Nasdaq:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
ORLANDO, FL / ACCESSWIRE / 2024年10月11日 / RedChip Companies將通過Bloomberg TV的贊助節目RedChip Small Stocks, Big Money Show，於本週六（10月12日）晚上7點（東部時間）播出與BioVie, Inc.（納斯達克股票代碼：BIVI）和Genetic Technologies Limited（納斯達克股票代碼：GENE，ASX股票代碼：GTG）的訪談。Bloomberg TV在美國約7300萬戶家庭中可收看。
Access the interviews in their entirety at:
Soligenix:
BioVie:
Genetic Technologies:
BioVie：
基因技術：
In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFα production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in late 2024, initiating a Phase 3 trial for Alzheimer's in late 2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.
在一次獨家採訪中，BioVie的總裁兼首席執行官Cuong Do將分享有關公司針對神經退行性疾病和肝病未滿足醫療需求的後期臨床項目管道的見解。BioVie的主要資產，bezisterim（前NE3107），已證明具有調節TNFα產生的能力，導致顯著的臨床改善。接受bezisterim治療的患者經歷了減少的炎症和胰島素抵抗、改善的運動控制和帕金森氏病（PD）的「早晨」症狀、認知功能和功能增強，以及阿爾茨海默病（AD）中更好的腦部成像掃描，以及降低的DNA甲基化水平。公司的戰略重點包括於2024年底啓動帕金森病的第二期試驗，2025年底啓動一項旨在爲阿爾茨海默病的新一日劑型bezisterim開展的第三期試驗，繼續就bezisterim的地理權利展開合作討論，並在確定適當合作伙伴後開始腹水症的第三期試驗。
Peter Rubinstein, Executive Chairman of Genetic Technologies, appears on the RedChip Small Stocks, Big Money show on Bloomberg TV to provide a corporate update. Genetic Technologies' EasyDNA platform has over $7 million in annual recurring revenues in the Paternity and Health and wellness space across global markets along with its expanding product portfolio including more than 50 risk assessment tests in 14 test categories covered by 25 patents granted and nine patents pending. In addition to its B2B commercialization strategy for its flagship geneType multi-risk test, Genetic Technologies is also focused on expanding its direct-to-consumer testing programs. The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of 17%+. A recent corporate restructure has dramatically reduced cash burn to allow the company to focus on sales and commercialization of its world leading technology.
Genetic Technologies的執行主席Peter Rubinstein將出現在Bloomberg TV的RedChip Small Stocks, Big Money Show上，提供公司更新。Genetic Technologies的EasyDNA平台在全球市場的親子關係和健康以及健康領域中擁有超過700萬美元的年度循環收入，其不斷擴大的產品組合包括超過50種風險評估測試，涵蓋14個測試類別，涵蓋25項已授權專利和9項待批專利。除了其旗艦基因型多風險測試的B20億商業化策略外，Genetic Technologies還專注於擴大其面向消費者的測試項目。預測基因組學的全球市場預計到2025年將達到460億美元，複合年增長率爲17%以上。最近的企業重組大大降低了現金流失，使公司能夠專注於銷售和商業化其全球領先的技術。
About BioVie Inc.
BioVie股份有限公司（NASDAQ：BIVI）是一家臨床階段公司，致力於開發治療神經系統和神經退行性疾病以及先進肝病的創新藥物療法。
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NFκB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit .
BioVie公司（納斯達克股票代碼：BIVI）是一家臨床階段公司，致力於開發治療神經系統和神經變性疾病以及先進肝病的創新藥物療法。在神經變性疾病中，該公司的藥物候選者bezisterim抑制ERk和NFκb的炎症活化（例如，TNF信號通路），從而導致神經炎症和胰島素抵抗，但不影響它們的穩態功能（例如，胰島素信號通路、神經元生長和存活）。這兩者都是阿爾茨海默病（AD）和帕金森病（PD）的驅動因素。在肝臟疾病方面，該公司的孤兒藥物候選者BIV201（持續靜脈注射替利普瑞辛），擁有美國食品和藥物管理局（"FDA"）的快速通道（Fast Track）地位，正在根據FDA的指導評估和討論BIV201用於治療慢性肝硬化引起的腹水的3期臨床測試設計。該活性劑已在美國和大約40個國家獲批用於治療先進肝硬化相關併發症。更多信息，請訪問。
About Genetic Technologies
關於基因技術
Genetic Technologies Limited (ASX:GTG)(Nasdaq:GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit .
基因技術有限公司（ASX股票代碼：GTG，納斯達克股票代碼：GENE）是一家多元化的分子診斷公司。作爲健康、健康和嚴重疾病基因型和EasyDNA品牌的全球基因組測試領導者。GTG提供癌症預測測試和評估工具，幫助醫生改善全球人群的健康結果。該公司擁有一個專有的風險分層平台，已經發展了十年之久，整合了臨床和遺傳風險，爲醫生和個人提供可執行的結果。在癌症學、心血管和代謝疾病的風險預測方面領先於世界，基因技術正在繼續開發風險評估產品。更多信息，請訪問。
About RedChip Companies
關於RedChip公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies是一家國際投資者關係、媒體和研究公司，專注於微型股和小型股公司。32年來，RedChip已爲其客戶提供了具體可衡量的成果。我們的每週在線電子報Small Stocks, Big Money發送給6萬名投資者。RedChip已經開發出業內最全面的服務平台，爲微型股和小型股公司提供以下服務：其股票研究的全球分發網絡；在美國主要城市進行的零售和機構路演；向股票經紀人、RIAs、機構和家族辦公室進行外出營銷；數字媒體投資者關係平台已經產生了數百萬的獨立投資者瀏覽量；投資者網絡研討會和群體電話；電視節目《Small Stocks, Big Money》，每週在Bloomberg美國播出；在本地和全國市場播放電視廣告；公司和產品視頻；網站設計；以及傳統的投資者關係服務，包括撰寫新聞稿、制定投資者演示文稿、季度電話會議腳本撰寫、戰略諮詢、資本籌集等。欲了解更多RedChip的產品和服務，請訪問：
To learn more about RedChip's products and services, please visit:
要了解更多關於RedChip公司產品和服務的信息，請訪問以下網站：
"Discovering Tomorrow's Blue Chips Today"
「發現明日的藍籌股」
Follow RedChip on LinkedIn:
在LinkedIn上關注RedChip：
Follow RedChip on Facebook:
在Facebook上關注RedChip：
Follow RedChip on Instagram:
在Instagram上關注RedChip：
Follow RedChip on Twitter:
在Twitter上關注RedChip：
Follow RedChip on YouTube:
在YouTube上關注RedChip：
Follow RedChip on Rumble:
在Rumble上關注RedChip：
Subscribe to our Mailing List:
訂閱我們的郵件列表：
Contact:
聯繫方式：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
--END--
--END--
SOURCE: RedChip
來源：RedChip
譯文內容由第三人軟體翻譯。
